MoFo News Item

MoFo Advises ORI Healthcare Fund On $100m Series C Investment Into Kymab

24 Nov 2016

Morrison & Foerster has represented Hong Kong-based venture capital fund ORI Healthcare Fund L.P. on its Series C investment into Kymab, a leading UK-based biopharmaceutical group focused on the discovery and development of fully human monoclonal antibody drugs.

The $100 million Series C financing was led by ORI, with participation by Shenzhen Hepalink Pharmaceutical Co., Ltd, as well as follow-on investments from existing shareholders, including the Wellcome Trust, Bill & Melinda Gates Foundation, and Malin Corporation plc. The funds will enable Kymab to advance its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies, the first of which starts clinical development in 2017.

The MoFo team was led by Graeme Sloan, head of corporate in London and a global chair of M&A, together with Palo Alto partner Janet Xiao, London corporate associates Greg Joynson and Robbie Somerville, and technology transactions associate Mercedes Samavi.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.